Download PDF
Thromb Haemost 1967; 18(01/02): 190-197
DOI: 10.1055/s-0038-1655028
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Action of a Proteolytic Enzyme Inhibitor on Blood Coagulation in Vitro

B Blombäck
1   Department of Blood Coagulation Research and Department of Experimental Surgery, Karolinska Institutet, Stockholm 60
,
Margareta Blombäck
1   Department of Blood Coagulation Research and Department of Experimental Surgery, Karolinska Institutet, Stockholm 60
,
P Olsson
1   Department of Blood Coagulation Research and Department of Experimental Surgery, Karolinska Institutet, Stockholm 60
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

The action of the kallikrein and trypsin inhibitor, Trasylol, has been studied in a three-stage thrombin generation system. It has been found that Trasylol inhibits one or several of the early reactions of blood coagulation. The inhibition of the early stages is dependent on the concentration of inhibitor, serum factors and factor VIII. The activation of factor V by tiger snake venom is not inhibited by Trasylol. The inhibition is most probably on one or several of the reactions preceding the factor V involved step.

Some other known antifibrinolytic agents have also been tested for anti-coagulation activity.

 

  • References

  • 1 Kunitz M, Northrop J. H. Isolation from beef pancreas of crystalline trypsinogen, trypsin, trypsin-inhibitor and an inhibitor-trypsin compound. J. gen. Physiol. 19: 991 1936;
    CrossrefPubMedGoogle Scholar
  • 2 Frey E. K, Kraut H. Ein neues Kreislaufhormon und seine Wirkung. Arch. exp. Path. Pharm. 133: 1 1928;
    PubMedGoogle Scholar
  • 3 Anderer F. A. Strukturuntersuchungen am Kallikrein-Inaktivator aus Rinderlunge. II. Bestimmung der Aminosäuresequenz. Z. Naturforsch 20b: 462 1965;
    PubMedGoogle Scholar
  • 4 Kassel B, Laskowski Sr M. The basic trypsin inhibitor of bovine pancreas. III. A progress report on the tryptic peptides. Biochem. biophys. Res. Commun. 17: 792 1964;
    PubMedGoogle Scholar
  • 5 Chauvet J, Nouvel G, Acher R. Structure primaire d’un inhibiteur pancréatique de la trypsine (Inhibiteur de Kunitz et Northrop. Biochim. biophys. Acta (Amst) 115: 130 1966;
    CrossrefPubMedGoogle Scholar
  • 6 Werle E, Maier L, Ringelmann E. Hemmung von Proteinasen durch Kallikrein-Inaktivatoren. Naturwissensch 39: 328 1952;
    PubMedGoogle Scholar
  • 7 Kraut H, Körbel-Enkhardt R. Das Verhalten des Kallikrein-Inaktivators aus Rinderparotis gegenüber proteolytischen Fermenten. Leistungen und Ergebnisse der neuzeitlichen Chirurgie. 62-68 Thieme, Stuttgart: 1958
    Google Scholar
  • 8 Marx R, Clemente P, Werle E, Appel W. Zum Problem eines Antidotes in der internen Thrombotherapie mit Fibrinolytika. Blut. 05: 367 1959;
    CrossrefPubMedGoogle Scholar
  • 9 Olsson P, Nordstrom S. The significance of postoperative variations in antithrombin. Thoraxchirurgie. 12: 176 1964;
    PubMedGoogle Scholar
  • 10 Nordstrom S, Olsson P, Blombäck M. Thromboplastin induced hypercoagulability and its prevention. Nature (Lond) 206: 632 1965;
    PubMedGoogle Scholar
  • 11 Soulier J. P. Proteolytic enzyme inhibitors. Their action on blood coagulation and fibrinolysis. Anticoagulants and fibrinolysins. 403 Macmillan of Canada: 1961
    Google Scholar
  • 12 Teger-Nilsson A-G. A procoagulant from retroplacental serum and its relation to factor X. Abstr. Xth Congr. Int. Soc. Haematol. Stockholm, Sweden; 1964. G: 32.
    Google Scholar
  • 13 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi. 10 4: 15 1956;
    PubMedGoogle Scholar
  • 14 Blombäck B, Blombäck M. A method for the assay of factor V. Scand. J. clin. Lab. Invest 15: 639 1963;
    CrossrefPubMedGoogle Scholar
  • 15 Blombäck B, Blombäck M, Francken I. v. Disc. Conf. Int. Com. Blood Clotting Factors, Stockholm, 1962. Thrombos. Diathes. haemorrh. (Stuttg) 09 Suppl. 2, 233 1963;
    PubMedGoogle Scholar
  • 16 Teger-Nilsson A-G. To be published..
    PubMedGoogle Scholar
  • 17 Blombäck B, Blombäck M. To the discussion on genetics and the interaction of blood clotting factors. Conf. Int. Com. Blood Clotting Factors, Amsterdam 1964. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 17: 59 1965;
    PubMedGoogle Scholar
  • 18 Hirs G. H. W. The oxidation of ribonuclease with performic acid. J. biol. Chem. 219: 611 1965;
    PubMedGoogle Scholar
  • 19 Brown W. D. Reduction of protein disulfide bonds by sodium borohydride. Biochim. biophys. Acta (Amst) 44: 365 1960;
    CrossrefPubMedGoogle Scholar
  • 20 Niewiarowski S, Stachurska J, Wegrzynowicz Z. Arginine esterase activity of the contact (Hageman) factor. Thrombos. Diathes. haemorrh. (Stuttg) 07: 514 1962;
    PubMedGoogle Scholar
  • 21 Kingdon H. S, Davie E. W, Ratnojf O. D. The reaction between activated plasma thromboplastin antecedent and diisopropylphosphofluoridate. Biochemistry 03: 166 1964;
    CrossrefPubMedGoogle Scholar
  • 22 Esnouf M. P, Williams W. J. The isolation and purification of bovine-plasma-protein which is a substrate for the coagulant fraction of Russel’s-Viper Venom. Biochem. J. 84: 62 1962;
    CrossrefPubMedGoogle Scholar
  • 23 Amris C. J. Inhibition of fibrinolytic and thromboplastic activity by Trasylol. Scand. J. Haemat. 03: 19 1966;
    PubMedGoogle Scholar
  • 24 Herschlein H. J, Steichele D. F. Die Hemmung der Hyperkoagulabilität des Blutes. Med. Welt (Stuttg) 1964; 1314.
    PubMedGoogle Scholar